PURPOSE: We explored the feasibility, toxicity, and preliminary results of a chemotherapy (CT) regimen, mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)/epidoxirubicin, bleomycin, and vinblastine (EBV)/lomustine (CCNU), doxorubicin, and vindesine (CAD), derived through hybridization, shortening, and intensification of a corresponding 10-drug alternating combination CAD/MOPP/doxorubicin, bleomycin, and vinblastine (ABV), effective in treatment of advanced Hodgkin's disease (HD). PATIENTS AND METHODS: Hybridization involved all drugs except CCNU and mechlorethamine, which were administered in alternating cycles; the length of therapy was reduced from nine to six cycles. The average projected drug doses during the six cycles were increased by 42%, with an overall 1.54 dose-intensification; epidoxorubicin was substituted for doxorubicin at equivalent tumoricidal doses. Radiotherapy (RT) was optional and its indications were limited. RESULTS: Eighty assessable patients with previously untreated, advanced or unfavorably presenting HD were treated in nine cooperating institutions between 1988 and 1991. RT was delivered to 22 patients. Remissions were complete (CR) in 75 patients (93%), partial in three (4%), and null in two (3%). The median relative dose-intensity was 0.71 for the overall regimen. Three of five patients who failed to achieve CR, and two of the four who relapsed, received lower relative dose-intensive cycles. Nonhematologic toxicity was acceptable, but there was considerable hematologic toxicity. Fatal gastrointestinal bleeding was seen in one patient. CONCLUSION: Caution is advised due to the short median follow-up period. Nevertheless, in addition to the excellent response rate, (1) the results were reached through abbreviation, intensification, and hybridization of an existing alternating regimen; (2) RT had limited use in this program, which may have contributed to lowering the risk of second tumors; and (3) the results were obtained in a multicenter study (a condition that often impairs results from clinical trials).

MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavourably presenting Hodgkin's disease. A report from the Italian Lymphoma Study Group / Pg, Gobbi; C., Pieresca; Federico, Massimo; N., Direnzo; Narni, Franco; E., Iannitto; G., Grignani; L., Cavanna; P., Avanzini; G., Partesotti; V., Pitini; Silingardi, Vittorio; E., Ascari; C., Mauri. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 11:(1993), pp. 712-719. [10.1200/jco.1993.11.4.712]

MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavourably presenting Hodgkin's disease. A report from the Italian Lymphoma Study Group

FEDERICO, Massimo;NARNI, Franco;SILINGARDI, Vittorio;
1993

Abstract

PURPOSE: We explored the feasibility, toxicity, and preliminary results of a chemotherapy (CT) regimen, mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)/epidoxirubicin, bleomycin, and vinblastine (EBV)/lomustine (CCNU), doxorubicin, and vindesine (CAD), derived through hybridization, shortening, and intensification of a corresponding 10-drug alternating combination CAD/MOPP/doxorubicin, bleomycin, and vinblastine (ABV), effective in treatment of advanced Hodgkin's disease (HD). PATIENTS AND METHODS: Hybridization involved all drugs except CCNU and mechlorethamine, which were administered in alternating cycles; the length of therapy was reduced from nine to six cycles. The average projected drug doses during the six cycles were increased by 42%, with an overall 1.54 dose-intensification; epidoxorubicin was substituted for doxorubicin at equivalent tumoricidal doses. Radiotherapy (RT) was optional and its indications were limited. RESULTS: Eighty assessable patients with previously untreated, advanced or unfavorably presenting HD were treated in nine cooperating institutions between 1988 and 1991. RT was delivered to 22 patients. Remissions were complete (CR) in 75 patients (93%), partial in three (4%), and null in two (3%). The median relative dose-intensity was 0.71 for the overall regimen. Three of five patients who failed to achieve CR, and two of the four who relapsed, received lower relative dose-intensive cycles. Nonhematologic toxicity was acceptable, but there was considerable hematologic toxicity. Fatal gastrointestinal bleeding was seen in one patient. CONCLUSION: Caution is advised due to the short median follow-up period. Nevertheless, in addition to the excellent response rate, (1) the results were reached through abbreviation, intensification, and hybridization of an existing alternating regimen; (2) RT had limited use in this program, which may have contributed to lowering the risk of second tumors; and (3) the results were obtained in a multicenter study (a condition that often impairs results from clinical trials).
1993
11
712
719
MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavourably presenting Hodgkin's disease. A report from the Italian Lymphoma Study Group / Pg, Gobbi; C., Pieresca; Federico, Massimo; N., Direnzo; Narni, Franco; E., Iannitto; G., Grignani; L., Cavanna; P., Avanzini; G., Partesotti; V., Pitini; Silingardi, Vittorio; E., Ascari; C., Mauri. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 11:(1993), pp. 712-719. [10.1200/jco.1993.11.4.712]
Pg, Gobbi; C., Pieresca; Federico, Massimo; N., Direnzo; Narni, Franco; E., Iannitto; G., Grignani; L., Cavanna; P., Avanzini; G., Partesotti; V., Pit...espandi
File in questo prodotto:
File Dimensione Formato  
MOPPEBVCAD hybrid.....pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 761.32 kB
Formato Adobe PDF
761.32 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/306111
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 26
social impact